Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Definitions

• the present invention relates to stable pharmaceutical formulations of levothyroxine sodium, useful in the treatment of thyroid hormone disorders in mammals, including humans.
• the invention also relates to a process for preparing such a formulation.
• Levothyroxine sodium is widely used in the treatment and/or prophylaxis of thyroid hormone disorders.
• Levothyroxine sodium is presently commercially available under the trademark EltroxinTM in the form of 50 ⁇ g and 100 ⁇ g tablets. These tablets contain levothyroxine sodium, lactose, magnesium stearate, acacia powder, sodium citrate and maize starch. Whilst levothyroxine sodium is relatively stable in pure form, pharmaceutical formulations containing levothyroxine sodium exhibit a relatively short shelf life, particularly under conditions of high light, heat, air and humidity (see " Kinetics of Degradation of Levothyroxin Sodium in Aqueous solution and in Solid State" , Chong Min Won , Pharmaceutical Research, Vol.
• the present invention is therefore directed at providing a stable solid dosage form of levothyroxine sodium. It is also desired that the solid dosage form disintegrates rapidly, thereby ensuring rapid release of the active ingredient, and is aesthetically acceptable and palatable to the patient.
• the present inventors have found that a pharmaceutical formulation comprising levothyroxine sodium, microcrystalline cellulose with a mean particle size less than 125 ⁇ m and pregelatinised starch provides a solid dosage form with improved stability and disintegration characteristics that is aesthetically acceptable and palatable to the patient.
• the present invention provides a pharmaceutical formulation comprising (a) an effective amount of levothyroxine sodium, (b) microcrystalline cellulose which has a mean particle size of less than 125 ⁇ m and is present in an amount of 60 to 85% w/w based upon the total weight of the formulation and (c) pregelatinised starch present in an amount of 5 to 30% w/w based upon total weight of the formulation.
• the pharmaceutical formulations of the present invention have improved stability such that they are stable to the extent that potency decreases by less than 5%, preferably less than 4%, more preferably less than 3% when the pharmaceutical formulation is stored at 25°C and 60% relative humidity for 12 months.
• the pharmaceutical formulations of the present invention have improved disintegration characteristics such that they have a disintegration time of less than 6 minutes, preferably less than 5 minutes, more preferably less than 4 minutes when tested in the disintegration test as described in the Examples section below.
• levothyroxine sodium is sodium (S)-2-amino-3-[4-(4-hydroxy-3,5- diiodophenoxy)-3,5-diiodophenyl]propionate.
• Levothyroxine sodium is the monosodium salt of the levo-rotatory isomer of thyroxine.
• Levothyroxine sodium may exist as one or more polymorphic forms, for example one or more crystalline forms, amorphous forms, phases, solid solutions and/or mixtures thereof. All such forms of levothyroxine sodium and/or mixtures thereof are encompassed by the present invention.
• the levothyroxine sodium for use in pharmaceutical formulations of the present invention is in hydrated form. More preferably, the levothyroxine sodium for use in pharmaceutical formulations of the present invention is in the pentahydrate form.
• the levothyroxine sodium is present in an amount less than 1% w/w based upon the total weight of the formulation, more preferably 0.01-0.30% w/w, even more preferably 0.03-0.25% w/w, most preferably 0.06-0.20% w/w.
• the minimum amount of levothyroxine sodium can vary, so long as an effective amount is utilised to cause the desired pharmacological effect.
• the microcrystalline cellulose has a mean particle size of ⁇ 100 ⁇ m, more preferably ⁇ 75 ⁇ m, even more preferably ⁇ 50 ⁇ m.
• the microcrystalline cellulose is selected from microcrystalline cellulose grade 101, 102, or 103, more preferably grade 101 or 102, most preferably grade 101.
• the term 'Grade 101' as used herein means material with nominal mean particle size 50 ⁇ m and moisture content ⁇ 5.0% in accordance with the European Pharmacopeia (2002).
• the term 'Grade 102' as used herein means material with nominal mean particle size 100 ⁇ m and moisture content
• the term 'Grade 103' as used herein means material with nominal mean particle size 50 ⁇ m and moisture content ⁇ 3.0% in accordance with the European Pharmacopeia (2002).
• the term 'Grade 200' as used herein means material with nominal mean particle size 180 ⁇ m and moisture content
• microcrystalline cellulose is sourced from FMC Corporation, JRS Rettenmaier or Sahne (Germany) or Wei Ming (Taiwan), more preferably Wei Ming (Taiwan).
• the microcrystalline cellulose is present in an amount of 60 to 85% w/w based on the total weight of the formulation, more preferably 65 to 80% w/w, most preferably 70 to 80% w/w.
• pregelatinised starch as used herein means partially pregelatinised starch typically containing about 5% of free amylose, 15% of free amylop ⁇ clin and 80% unmodified starch. It is produced by subjecting moistened starch to mechanical pressure in order to rupture some or all of the starch granules. The resultant material is ground and it's moisture content adjusted such that it possesses good flow and compression characteristics. Typical cold water solubility of partially pregelatinised starch, e.g. Starch 1500 (Colorcon) is 10-20%. Pregelatinised starch is further defined in the European Pharmacopea (2002) which is included herein by reference. Preferably, the pregelatinised starch is present in an amount of 5 to 30% w/w based on the total weight of the formulation, more preferably 10 to 30% w/w, most preferably 15 to 25% w/w.
• the ratio of microcrystalline cellulose:pregelatinised starch is in the range of 2:1 to 15:1 , more preferably 2.5:1 to 8:1 , most preferably 3:1 to 5:1.
• the microcrystalline cellulose and pregelatinised starch contain water.
• the water comprises 3-6% w/w based on the total weight of the formulation, more preferably about 4.5% (e.g. 4.5% - 5.0%).
• the pharmaceutical formulation includes one or more glidants/lubricants.
• Suitable glidants/lubricants for use in the present invention include colloidal silicon dioxide, talc, magnesium stearate, zinc stearate, calcium stearate, sodium stearate fumarate and sodium magnesium lauryl sulphate.
• the glidants/lubricants are selected from one or more of: colloidal silicon dioxide, talc and magnesium stearate.
• the glidant/lubricant is present in an amount 1-10% of the total weight of the formulation, more preferably 2-9% of the total weight of the formulation, most preferably 3- 8% of the total weight of the formulation.
• talc is present in an amount 1-5% of the total weight of the formulation, more preferably 2-4% of the total weight of the formulation, most preferably 2.5-3.5% of the total weight of the formulation.
• colloidal anhydrous silica is present in an amount 1-5% of the total weight of the formulation, more preferably 1-3% of the total weight of the formulation, most preferably 1.5-2.5% of the total weight of the formulation.
• magnesium stearate is present in an amount 0.1-5% of the total weight of the formulation, more preferably 0.5-4% of the total weight of the formulation, most preferably 0.8-1.5% of the total weight of the formulation.
• the pH of the pharmaceutical formulation is in the range pH 6.8 to 8.2, preferably pH 7.2 to 7.8 when suspended in water in a ratio wate ⁇ pharmaceutical formulation of 10:1.
• the formulations of the invention may, if desired, further include one or more pharmaceutically acceptable excipients. All such excipients must be “pharmaceutically acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
• Pharmaceutically acceptable excipients may include colours, flavours e.g. menthol, sweeteners e.g. mannitol, preservatives, stabilisers, antioxidants and any other excipients known to those skilled in the art.
• the present invention covers all combinations of particular and preferred groups described hereinabove.
• the present invention provides a pharmaceutical formulation for use in medical therapy, e.g. in the treatment of thyroid hormone disorders in an animal, e.g. a mammal such as a human.
• Levothyroxine and other thyroid hormones are known to serve as hormone replacement therapy when the thyroid function has been reduced or is completely absent for a variety of disease states, including, hypothyroidism, myxedema, cretinism and obesity, preferably hypothyroidism.
• the amount required of levothyroxine sodium will depend on a number of factors including the severity of the condition to be treated and the identity of the recipient and will ultimately be at the discretion of the attendant physician or veterinarian.
• a physician will determine the actual dosage which will be most suitable for an individual subject.
• the specific dose level and frequency of dosage for any particular individual may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual undergoing therapy.
• a suitable effective dose will be in the range 1.0 to 6.0 ⁇ g per kilogram bodyweight of recipient per day, preferably in the 1.5 to 5.0 ⁇ g per kilogram bodyweight per day (unless otherwise indicated, all weights are calculated with respect to the free base active ingredient).
• the desired dose is preferably presented as one, two, three or four sub-doses administered at appropriate intervals throughout the day.
• These sub-doses may be administered in unit dosage forms, for example, containing about 10 to 300 ⁇ g, preferably 10-200 ⁇ g, more preferably 25-150 ⁇ g, of active ingredient per unit dose form, most preferably 50 ⁇ g or 100 ⁇ g of active ingredient per unit dose form.
• a 50 ⁇ g tablet may comprise 0.0425-0.0575mg levothyroxine sodium, 50- 60mg microcrystalline cellulose, 12-17mg pregelatinised starch, 2-3mg talc, 1-2mg colloidal anhydrous silica and 0.5-1 mg magnesium stearate.
• a 100 ⁇ g tablet may comprise 0.085-0.115mg levothyroxine sodium, 100-120mg microcrystalline cellulose, 24-34 pregelatinised starch, 4-6mg talc, 2-4 mg colloidal anhydrous silica and 1-2mg magnesium
• the pharmaceutical formulation is preferably administered orally and is preferably in the form of a tablet.
• the composition according to the present invention may also be administered in the form of capsules, caplets, gelcaps, pills, and any other oral dosage forms known in the pharmaceutical art.
• treatment and derivatives such as “treating” as used herein includes both treatment and prophylaxis. Prophylaxis is relevant in relation to protection against such conditions such as hypothyroidism.
• a further aspect of the invention provides a process for preparing a pharmaceutical formulation according to the invention.
• the tablet may be prepared either by a wet granulation or by a direct compression process.
• a direct compression process is used, e.g. using a conventional high speed rotary press.
• the pharmaceutical formulation is prepared by making an initial preparation of a triturate of levothyroxine sodium and subsequently incorporating the triturate into the tablet formulation.
• a triturate of levothyroxine sodium comprises levothyroxine sodium and a suitable carrier, e.g. microcrystalline cellulose, wherein the levothyroxine sodium is present in a greater concentration in the triturate than in the final tablet formulation.
• the triturate comprises 2-3% w/w levothyroxine sodium of total weight of triturate. Preparation using a triturate improves distribution of the low concentration of drug throughout the blend and uniformity in the tablets i.e. homogeneous incorporation.
• the process comprises the steps of: (a) preparing a triturate of levothyroxine sodium and microcrystalline cellulose, (b) mixing the triturate with the remaining components of the pharmaceutical formulation, and (c) compression.
• Levothyroxine sodium can be obtained from the thyroid gland of domesticated animals, or alternatively the hormone can be prepared synthetically.
• Methods for making active ingredient are disclosed in Hagers Handbuch der pharmazeutician für fürtechnik, - 5., vollst. Neubearb., Bd. ⁇ .Stoffe: E-O / F... Von Bruchhausen; (Hrgs.).Bearb... von M. Albinus - 1993, Springer-Verlag Berlin Heidelberg 1993, pages 733 - 734; S. Rolski, Chemia srodk ⁇ w leczniczych, str. 654-655, PZWL, Warszawa 1968. The contents of which are incorporated herein by reference.
• the formulation may be introduced into a container which is then closed.
• the container may be sealed, e.g. by LDPE tamper-evident snap fit closures. It may be a single-dose or multi-dose container.
• the container may be bottles, jars, bags or sachets. Sachets, especially foil sachets (foil-foil blisters), are particularly suitable for single dose packaging. Bottles, particularly high density polyethylene (HOPE) or polypropylene (PP) bottles are particularly suitable for multi-dose packaging.
• HOPE high density polyethylene
• PP polypropylene
• Example 1 (b) differed from Example 1 (a) in that a preblend of the remainder of microcrystalline cellulose and colloidal silicon dioxide was made before blending with the levothyroxine sodium triturate and pregelatinised starch.
• Example 2 Stability of Levothyroxine Sodium Tablets. Comparative stability studies of levothyroxine sodium tablets were based on testing of levothyroxine sodium and total impurities contents after storage of tablets at (i) 40°C/75%RH, (ii) 30°C/60%RH, and (iii) 25°C/60%RH. Suitable HPLC methods were applied. Stability was measured in terms of levothyroxine sodium content and total impurities content:
• Total impurities contents were determined using the assay method for levothyroxine sodium tablets in the British Pharmacopoeia 2002 with a sample concentration of 50 ⁇ g/ml, sample solvent: methanol and 0.02 M aqueous NaOH (1 :1 ), an injection volume of 10O ⁇ l and a phase flow rate of 1.5ml/min.
• Levothyroxine sodium contents were determined using the assay method for levothyroxine sodium tablets in the British Pharmacopoeia 2002 using a sample concentration of 50 ⁇ g/ml, sample solvent: methanol and 0.02 M aqueous NaOH (1 :1) and phase flow rate of 1.5 ml/min.
• the data shows that at 3-9 months after storage a higher levothyroxine sodium content is maintained in tablets according to Example 1 (b) than in the marketed formulation of Eltroxin TM and total impurities are lower in tablets according to Example 1(b) than in marketed formulation of Eltroxin TM.
• the data shows that a higher levothyroxine sodium content is maintained and the total impurities are lower when microcrystalline cellulose with a mean particle size of 50 ⁇ m or 100 ⁇ m compared to 180 ⁇ m is used in the levothyroxine sodium formulation.

Landscapes

• Health & Medical Sciences (AREA)
• Public Health (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Endocrinology (AREA)
• Diabetes (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (16)

Applications Claiming Priority (2)

Publications (2)

Family

ID=27741962

Family Applications (1)

Country Status (28)

Cited By (6)

Families Citing this family (10)

Family Cites Families (13)

• 2003
  • 2003-07-10 GB GBGB0316206.2A patent/GB0316206D0/en not_active Ceased
• 2004
  • 2004-07-08 TW TW093120412A patent/TWI329026B/zh not_active IP Right Cessation
  • 2004-07-08 JP JP2006518170A patent/JP4880457B2/ja not_active Expired - Lifetime
  • 2004-07-08 DE DE602004018142T patent/DE602004018142D1/de not_active Expired - Lifetime
  • 2004-07-08 PT PT04740922T patent/PT1643976E/pt unknown
  • 2004-07-08 KR KR1020067000484A patent/KR101136655B1/ko not_active Expired - Lifetime
  • 2004-07-08 EP EP04740922A patent/EP1643976B1/en not_active Expired - Lifetime
  • 2004-07-08 PL PL04740922T patent/PL1643976T3/pl unknown
  • 2004-07-08 CN CNB2004800197743A patent/CN100430051C/zh not_active Expired - Lifetime
  • 2004-07-08 AT AT04740922T patent/ATE415949T1/de active
  • 2004-07-08 BR BRPI0412391A patent/BRPI0412391B8/pt not_active IP Right Cessation
  • 2004-07-08 WO PCT/EP2004/007667 patent/WO2005004849A2/en not_active Ceased
  • 2004-07-08 CA CA2531853A patent/CA2531853C/en not_active Expired - Lifetime
  • 2004-07-08 AU AU2004255466A patent/AU2004255466B2/en not_active Expired
  • 2004-07-08 AR ARP040102405A patent/AR045719A1/es not_active Application Discontinuation
  • 2004-07-08 NZ NZ544174A patent/NZ544174A/en not_active IP Right Cessation
  • 2004-07-08 RU RU2006104009/15A patent/RU2349345C2/ru active
  • 2004-07-08 MX MXPA06000353A patent/MXPA06000353A/es active IP Right Grant
  • 2004-07-08 DK DK04740922T patent/DK1643976T3/da active
  • 2004-07-08 US US10/564,148 patent/US7955621B2/en not_active Expired - Lifetime
  • 2004-07-08 ES ES04740922T patent/ES2319193T3/es not_active Expired - Lifetime
  • 2004-07-08 MY MYPI20042725A patent/MY140127A/en unknown
• 2005
  • 2005-12-15 ZA ZA200510224A patent/ZA200510224B/en unknown
  • 2005-12-15 IL IL172619A patent/IL172619A/en active IP Right Grant
  • 2005-12-30 CO CO05131486A patent/CO5700710A2/es not_active Application Discontinuation
• 2006
  • 2006-01-06 MA MA28702A patent/MA27898A1/fr unknown
  • 2006-01-13 NO NO20060208A patent/NO338465B1/no unknown
  • 2006-02-07 IS IS8287A patent/IS2616B/is unknown
• 2011
  • 2011-07-21 JP JP2011160067A patent/JP2011213736A/ja active Pending

Also Published As

Similar Documents

Legal Events